10 results about "CCL19" patented technology

The invention belongs to the technical field of biological medicine, and discloses a medicine for in-vivo engineering CAR-T and a preparation method thereof. The drug provided by the invention comprises a first RNA and a second RNA which are used for coding a chimeric antigen receptor in a specific molar ratio, the second RNA is used for coding at least two cytokines of CCL19, IL-17, IL-15, IL-2 or IL-24, by adopting the drug, the gene delivery efficiency and targeting of in-vivo engineered CAR-T can be improved, better T cell transformation and CAR + T cell generation effects are realized, the CAR-T cell depletion is reduced, and the drug has a good application prospect. According to the present invention, the CAR-T gene is constructed, such that the CAR-T gene can survive for a long time in the tumor microenvironment and continuously provide the treatment effect, has the excellent anti-tumor treatment effect, has the excellent application prospect in the in-vivo engineering CAR-T treatment, and has the important significance on the promotion of the efficient, safe and economical development of the CAR-T treatment.

An object according to certain aspect(s) of the present invention is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell. Another object according to certain aspect(s) of the present invention is to provide an immunocompetent cell targeting mesothelin. An immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, interleukin 7 (IL-7), and chemokine (C-C motif) ligand 19 (CCL19) is produced. It is preferred that: the cell surface molecule specifically recognizing human mesothelin should be chimeric antigen receptor (CAR) having single chain antibody, a transmembrane region, and a signaling region that induces the activation of the immunocompetent cell; and the heavy chain variable region and the light chain variable region should be connected via a peptide linker consisting of a 2- to 30-amino acid sequence.

The invention discloses an application of an FHL2-L4 peptide fragment in preparation of a medicine for treating atherosclerosis. The invention particularly relates to an application of an FHL2-L4 peptide fragment, an fhl-l4 gene, an expression cassette, a recombinant vector, a recombinant cell or recombinant bacteria, an overexpression vector, sgRNA, a gene knockout vector and a correspondingly packaged virus in preparation of medicines for treating atherosclerosis. It is found for the first time that the L4 peptide fragment serves as the minimum functional unit for promoting atherosclerosis of FHL2, plaque formation can be remarkably inhibited through specific knockout of the L4 peptide fragment, and the effect is directly related to CCL19 / 21 signal channel inhibition. Based on this, gene editing or antagonistic peptide design of targeting L4 can be used as a breakthrough strategy for atherosclerosis treatment.

A composition for preventing or treating cancer or infectious disease is disclosed. The composition contains, as an active ingredient, a pluripotent stem cell-derived immune cell expressing IL-7, CCL19, or a combination thereof. The composition provides a multifaceted and synergistic therapeutic effect derived from the complementary immune response of the patient's endogenous T cells and the injected natural killer cells, by administering only a therapeutically effective amount of immune cells other than T cells, specifically natural killer cells. The natural killer cells of the composition may also be co-administered with exogenous T cells to allow these different cell populations to act more intensively at the lesion site. The composition is based on the differentiation of pluripotent stem cells, specifically induced pluripotent stem cells (iPSCs) into immune cells, thus can be used to generate an unlimited supply of allogenic or autologous cells as needed.

This application relates to enhancers of T cells or B cells with memory function, inhibitors of malignant tumor recurrence, and inducers of memory function in T cells or B cells. The object of this invention is to provide enhancers of endogenous T cells or B cells with memory function and inhibitors of malignant tumor recurrence for long-term, sustained rejection of malignant tumors. Enhancers of T cells or B cells with memory function in the recipient, and inducers of memory function in T cells or B cells in the recipient, are prepared, wherein the enhancers and inducers comprise a nucleic acid delivery medium, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding chemokine (C-C motif) ligand 19 (CCL19). Additionally, an inhibitor of malignant tumor recurrence is prepared, comprising a nucleic acid delivery medium, a nucleic acid encoding interleukin-7 (IL-7), and a nucleic acid encoding CCL19.

The application discloses a detection method of a triple negative breast cancer immunotherapy efficacy prediction marker CCL19. The application provides application of CCL19 as a marker in preparation of a breast cancer immunotherapy efficacy and / or prognosis prediction product. A triple negative breast cancer immunotherapy efficacy and prognosis prediction kit comprising a CCL19 protein detection reagent and optionally an instruction is also provided. Application of a CCL19 molecule in combination with a second therapeutic agent in preparation of an antitumor drug is also provided. The application greatly fills the vacancy of triple negative breast cancer immunotherapy efficacy prediction liquid biopsy, and realizes precise prediction of immunotherapy efficacy in a noninvasive, rapid and low-cost manner.

The invention belongs to the technical field of biomedicine, and relates to an exosome vaccine as well as a preparation method and application thereof, and the exosome vaccine is an exosome which expresses coexistence of CCL19 full-length CDS and neoantigen through lentivirus construction by utilizing HEK-293 FT cells. According to the exosome vaccine, antigen presenting cells are targeted in a CCL19-CCR7 receptor-ligand mediated targeted delivery mode, the antigen presenting cell uptake and delivery efficiency of the Neo-CCL19Exos vaccine is improved, MHC-I dependent antigen cross presentation is efficiently activated, TLS formation in liver cancer is promoted, liver cancer is induced to be converted from cold tumor to hot tumor, and liver cancer is induced to be cured. Therefore, a novel method is provided for designing vaccines and enhancing the immune curative effects of the vaccines in the future.

An anticancer agent for solid cancer, which contains, as an active ingredient, human parainfluenza virus type 2 that expresses at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15 and IL-18, or a combination of said cytokine with CCL19 and / or CCL21, or a mutant thereof having the same function.

The invention belongs to the technical field of biological medicines, and particularly discloses a CCR7 affinity peptide, a coding nucleic acid and application of the CCR7 affinity peptide. According to the invention, CCR7 is taken as a target molecule, and the CCR7 affinity peptide CRBP3 is obtained through a phage display dodecapeptide library high-throughput screening technology. In-vitro function experiments show that the CRBP3 can efficiently target CCR7 + DC, promote phagocytosis of CCR7 + DC on antigens, stimulate T cell proliferation and enhance T cell functions, and the CRBP3 does not block a CCR7-CCL19 / CCL21 pathway and does not inhibit migration of CCR7 + DC. In-vivo anti-tumor experiments show that the CCR7 affinity peptide coupled polypeptide vaccine can improve presentation of antigens, initiate powerful specific CD8 + T cellular immune response and remarkably inhibit growth of tumors, has the effects of inhibiting tumor recurrence for a long time and establishing immune memory, and can provide new effective treatment strategies and candidates for improving the anti-tumor effect.